clinical trial · NCT05737485
Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
Primary Ciliary DyskinesiaRCT1100
brief summary
This is the first-in-human study with RCT1100 and is designed to provide initial safety and tolerability data for future clinical studies.
started
Feb 18, 2023
primary completion
Jul 25, 2024
completion
Jan 13, 2025
last updated
Apr 29, 2025
detailed description
The primary objective of this study is to assess the safety and tolerability of a single ascending dose of inhaled RCT1100 administered via nebulizer to healthy participants and patients with Primary Ciliary Dyskinesia caused by a pathogenic mutation in the DNAI1 Gene.
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study, in Healthy Adult Participants and Open-Label Single Ascending Dose Study in Adults With Primary Ciliary Dyskinesia Caused by Pathogenic Mutations in the DNAI1 Gene to Evaluate the Safety and Tolerability of RCT1100
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol